EYPT News and Press, EyePoint Pharmaceuticals Inc. From 07/11/22

WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej ...

WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the election of Anthony (Tony) Ad...

China's National Medical Products Administration approved EyePoint Pharmaceuticals (NASDAQ:EYPT) and OcuMension Therapeutics' (OTCPK:OCUTF) intravitreal implant Yutiq to treat chronic non-infectious uveitis affecting the posterior segment of the eye. Uveitis is a type of eye inflamm...

WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics (HKS...

WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that a late-breaking abstrac...

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive...

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2022 Earnings Conference Call May 04, 2022 08:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President and CEO Jay Duker - COO Scott Jones - CCO Conference Call Participants Georgi Yordanov - Cowen Yatin Suneja - Guggenheim Securities...

EyePoint Pharmaceuticals (NASDAQ:EYPT) signed a license agreement with China-based Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau and Taiwan (the Territory). EyePoint said it will retain global ophthalmic rights for EYP-1901 in the rest of the ...

EyePoint Pharmaceuticals press release (NASDAQ:EYPT): Q1 GAAP EPS of -$0.56 in-line. Revenue of $9.3M (+27.4% Y/Y) misses by $0.59M. Cash and investments at March 31, 2022 totaled $190.8 million compared to $211.6 million at December 31, 2021. We expect the cash ...

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 – ...